Shares of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) have been given an average rating of “Hold” by the nine brokerages that are currently covering the stock. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $41.90.

RDY has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “buy” rating and set a $61.00 price target for the company in a research note on Tuesday, July 12th. HSBC lowered shares of Dr. Reddy’s Laboratories from a “hold” rating to a “reduce” rating in a research report on Wednesday, July 27th. Jefferies Group lowered shares of Dr. Reddy’s Laboratories from a “hold” rating to an “underperform” rating and cut their target price for the company from $45.00 to $41.90 in a research report on Wednesday, July 27th. Finally, Credit Suisse Group AG lowered shares of Dr. Reddy’s Laboratories from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 26th.

Shares of Dr. Reddy’s Laboratories (NYSE:RDY) opened at 46.54 on Monday. The stock’s 50 day moving average is $46.59 and its 200 day moving average is $46.71. Dr. Reddy’s Laboratories has a 52-week low of $40.67 and a 52-week high of $68.00. The stock has a market cap of $7.70 billion, a PE ratio of 35.18 and a beta of 0.78.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Tuesday, July 26th. The company reported $0.00 EPS for the quarter. Dr. Reddy’s Laboratories had a net margin of 10.09% and a return on equity of 12.27%. The firm earned $479 million during the quarter, compared to analyst estimates of $557 million. Equities research analysts forecast that Dr. Reddy’s Laboratories will post $1.33 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. Bank of Montreal Can purchased a new position in Dr. Reddy’s Laboratories during the second quarter worth $4,433,000. Fisher Asset Management LLC raised its position in Dr. Reddy’s Laboratories by 9.5% in the second quarter. Fisher Asset Management LLC now owns 5,227,024 shares of the company’s stock worth $284,611,000 after buying an additional 451,679 shares during the last quarter. Creative Planning raised its position in Dr. Reddy’s Laboratories by 11.8% in the second quarter. Creative Planning now owns 8,009 shares of the company’s stock worth $410,000 after buying an additional 844 shares during the last quarter. Vontobel Asset Management Inc. raised its position in Dr. Reddy’s Laboratories by 1.9% in the second quarter. Vontobel Asset Management Inc. now owns 1,270,516 shares of the company’s stock worth $65,765,000 after buying an additional 23,410 shares during the last quarter. Finally, TT International raised its position in Dr. Reddy’s Laboratories by 2.7% in the second quarter. TT International now owns 44,976 shares of the company’s stock worth $2,304,000 after buying an additional 1,167 shares during the last quarter. Institutional investors and hedge funds own 16.18% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter (OTC) finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

5 Day Chart for NYSE:RDY

Receive News & Stock Ratings for Dr. Reddy's Laboratories Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd. and related stocks with our FREE daily email newsletter.